The multinational healthcare firm, Viatris Inc., has shared news of the tentative approval from FDA)for an abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg oral suspension tablet New Drug Application .
InvIOs GmbH revealed today that it has launched patient enrollment for a Phase 1b trial of its innovative autologous cell therapy, APN401, focusing on solid tumor patients.
The European Union Commission has approved Pfizer's ABRYSVO™ to protect infants and the elderly from Respiratory Syncytial Virus infections via maternal vaccination.
RLYB116, a potential long-acting solution, is a subcutaneously administered C5 inhibitor which is currently being developed for managing patients with complement-mediated diseases.